You are here: Home > Blogs
Company

The diabetes battle: Will Novo’s oral GLP-1 knock Trulicity off its perch?

  • December, 11 2018
  • 1325

Timing is of the essence for Novo Nordisk. The Danish company may use its priority review voucher to accelerate oral GLP-1 agonist candidate, semaglutide, past the regulators – though a decision is not confirmed. Buying a few more weeks – or months – to e

Company

Bayer Cuts Internal R&D, Looking Outside

  • December, 11 2018
  • 878

Bayer’s late November announcement of 12,000 job cuts and a focus on ‘collaborative research models’ and ‘external innovations’ to fuel pharma R&D is not a surprise. Rumors had been swirling for months in the German press. Bayer board member and innov

Related Videos
Oliver Spray Analyst
Oliver Spray Analyst

M&A Outlook for 2018

Amanda Mucklus Analyst
Amanda Mucklus Analyst

Diversification Strategy

Pharma Intelligence
Pharma Intelligence

Biosimilars Battlegrounds

Pharma Intelligence
Pharma Intelligence

Q4 2018 Outlook Webinar

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726
informa
Call Back